Methods of treating solid tumors, such as squamous cancer (such as head and neck squamous cell carcinoma), ER PR HER2/neu (triple-negative) breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, and gynecological malignancy, in subjects are described. The methods may comprise administering an anti-FGFR2b antibody to the subject.

The invention provides an anti-carcinoembryonic antigen (CEA) antibody for use in detecting CEA, treating disorders associated with CEA expression, diagnosing cancers characterized by aberrant CEA expression, and predicting effectiveness of cancer drug therapies. Anti-CEA antibodies, antibody fragments, monoclonal antibodies, antibody conjugates, compositions comprising the described antibodies and methods of their use are provided.

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

A process for the synthesis of a glycoside, comprising the step of; performing hydrolysis of a methyl ester glycoside in the presence of a base in water, to form a glycoside,
wherein the propensity to reform the methyl ester glycoside is reduced. The invention also extends to methods for the detection or prognosis of cancer using a glycoside obtained by said process

Provided are methods and systems of clinical tier grading to assess prognosis of a treatment (e.g., an immune checkpoint inhibitor) efficacy and/or its safety.

Disclosed in the present invention are a monoclonal antibody (YWHG-4) against HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) and use thereof. The antibody (YWHG-4) is produced by the hybridoma deposited under CCTCC NO: 2021204, and an antigenic peptide (RGYYNQSEASSHTLQWMIGC) of amino acid sequences at positions 106-126 of a heavy chain of HLA-G molecules is used as an immunogen. Provided in the present invention are a nucleotide encoding the YWHG-4 antibody of the present invention and an encoded amino acid sequence thereof. Further provided in the present invention is use of the YWHG-4 antibody in the detection of the HLA-G isoforms (HLA-G1, HLA-G4, HLA-G5) by means of immunoblotting, immunohistochemistry, ELISA and flow cytometry.

The present invention relates to prognostic and therapeutic methods for the treatment of cancer (e.g., lung cancer, e.g., non-small cell lung cancer (NSCLC)) using expression levels of tumor-associated macrophage (TAM) and regulatory T cell (Treg) genes. In particular, the invention provides methods for patient selection and treatment.

The present invention relates to the treatment of specific patient groups using an anti-GDF15 antibody in combination with a checkpoint inhibitor. Furthermore, the invention also provides a dosage regimen for the treatment of cancers in a human patient using an anti-GDF15 antibody.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.

A reagent kit, staining method, and application for combining dual immunohistochemistry with elastin fiber staining. The reagent kit includes a combination of primary antibodies, consisting of anti-CK7 and anti-CD34 monoclonal antibodies from different species, such as rabbit anti-human CK7 monoclonal antibody and mouse anti-human CD34 monoclonal antibody. By selecting CK7 and CD34 as the primary antibody combination, the growth pattern of tumor epithelium can be accurately indicated, and the proliferation and thickening of alveolar septal fibrous tissue caused by tumors can be clearly revealed, as opposed to structural changes of alveoli induced by other factors. Combined with independent Victoria blue staining, the elastin fibers of the walls of arteries and veins, as well as the pleura of the lungs, can be clearly visualized, aiding in the assessment of the integrity of elastin fibers on the lung surface and in determining the extent of tumor infiltration.